Physician profile
Pablo E Amador
NPI 1962427849
$912.31
in general payments reported to CMS, 2019-2025
13 companies · $551 in 2025
The $551 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $233 · 2021: $113 · 2022: $15.29 · 2025: $551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $300 · Food and Beverage: $251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $300.00 |
| Food and Beverage | $250.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $300.00 | 2025 | |
| Amgen INC. | $125.01 | 2025 | Repatha |
| Zoll Respicardia, INC. | $123.43 | 2019 | |
| Medtronic Vascular, INC. | $109.61 | 2019 | |
| Abbvie INC. | $96.00 | 2021 | |
| Aimmune Therapeutics, INC. | $29.96 | 2025 | Vowst |
| Vertex Pharmaceuticals Incorporated | $24.92 | 2025 | |
| Inspire Medical Systems, INC. | $24.27 | 2025 | Inspire |
| Alexion Pharmaceuticals, INC. | $24.00 | 2025 | Ultomiris |
| Optinose US, INC. | $22.63 | 2025 | |
| Amarin Pharma, INC. | $17.19 | 2021 | |
| Idorsia Pharmaceuticals US INC | $15.29 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pablo Amador listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.